Search

Memorial Sloan Kettering Cancer Center researchers join with experts from international institutions to estimate the potential impact of scaling up the availability of treatment and imaging modalities on breast cancer survival globally, together with improvements in quality of care.

… Thursday, August 19, 2021 Female breast cancer is the most commonly diagnosed cancer in the world, with wide variations in reported survival by country. Women in low-income and middle-income countries (LMICs) in particular face several barriers to breast cancer services, including diagnostics and treatment

Convection enhanced delivery, an innovative technique that directly infuses a therapeutic agent into a brain tumor through a cannula, bypassing the blood-brain barrier, is safe and feasible for treating diffuse intrinsic pontine glioma in children.

… Friday, August 14, 2020 Convection enhanced delivery (CED), an innovative technique that directly infuses a therapeutic agent into a brain tumor through a cannula, bypassing the blood-brain barrier (BBB), is safe and feasible for treating diffuse intrinsic pontine glioma (DIPG), according to our experience

Memorial Sloan Kettering Cancer Center (MSK) is collaborating with Triomics, an oncology-focused generative artificial intelligence company, to deploy Triomics’ artificial intelligence (AI)-powered clinical trial matching and screening platform in MSK’s active clinical trials.

… Tuesday, November 4, 2025 Memorial Sloan Kettering Cancer Center (MSK) is collaborating with Triomics, an oncology-focused generative artificial intelligence company, to deploy Triomics’ artificial intelligence (AI)-powered clinical trial matching and screening platform in MSK’s active clinical trials

Learn about the latest research on why more young adults are developing cancer, from investigators across MSK.

… Monday, January 5, 2026 It’s a disturbing mystery that has drawn the attention of investigators from across Memorial Sloan Kettering Cancer Center (MSK). Why are a growing number of young people under 50 being diagnosed with over a dozen forms of cancer around the world? This trend is especially worrying

Obtenga las últimas actualizaciones de investigación de investigadores de MSK sobre por qué tantos adultos jóvenes tienen cáncer.

… Monday, January 5, 2026 Es un misterio inquietante que ha llamado la atención de los investigadores de todo Memorial Sloan Kettering Cancer Center (MSK). ¿Por qué cada vez más se diagnostica a jóvenes menores de 50 años con más de una decena de formas de cáncer en todo el mundo? Esta tendencia es especialmente

Analysis of long-preserved single cells on pathology slides aims to provide new clues about the genes that make breast cancer more aggressive.

… Friday, February 10, 2017 Summary A new technique that enables researchers to study single cells from older samples taken from people with breast cancer is opening the door to new findings about genetic changes that make cancer aggressive. Highlights MSK has an incredible storehouse of tumor samples

Scientists have learned that cutting a T cell’s brakes can have unexpected consequences.

… Monday, June 17, 2019 Summary Scientists at the Sloan Kettering Institute have discovered that a particular protein controls whether an immune cell makes braking molecules, such as PD-1. Immune cells lacking this protein behave in an unexpected way. The 2018 Nobel Prize in Physiology or Medicine went

Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused February 9 issue of Cell, the article — “Implementing Genome-Driven Oncology” — presents a critically self-reflective but solutions-focused perspective on this approach to cancer treatment.

… Thursday, February 9, 2017 Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

… Wednesday, August 25, 2010 A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma . Investigators at Memorial Sloan Kettering Cancer Center and colleagues

… Monday, November 9, 2020 Miriam Lorena Murray estaba en la mejor condición física de su vida cuando recibió una desgarradora noticia: su médico le diagnosticó, cáncer de mama. “Estaba en un estado dos ya pasando a un estado tres y sin ningún síntoma, viéndome espectacular”, contó Miriam Lorena de 50